Abiraterone in Metastatic Prostate Cancer without Previous ChemotherapyCharles J. Ryan, Dana E. Rathkopf, Matthew R. Smith et al.|New England Journal of Medicine|2012Cited by 2.8k
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Johann S. de Bono, Jin Hui Li et al.|The Lancet Oncology|2012Cited by 1.4k
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 studyCharles J. Ryan, Dana E. Rathkopf, Matthew R. Smith et al.|The Lancet Oncology|2015Cited by 1.4k
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell LymphomaElise A. Olsen, Jean Nichols, Madeleine Duvic et al.|Journal of Clinical Oncology|2001Cited by 610
Updated Interim Efficacy Analysis and Long-term Safety of Abiraterone Acetate in Metastatic Castration-resistant Prostate Cancer Patients Without Prior Chemotherapy (COU-AA-302)Dana E. Rathkopf, Fred Saad, Matthew R. Smith et al.|European Urology|2014Cited by 273